

Maine Naloxone Distribution Initiative

Project-To-Date Totals through September 30, 2025

Prepared by the Margaret Chase Smith Policy Center
University of Maine

In July 2019, the Maine Naloxone Distribution Initiative (MNDI) launched an overdose education, prevention, and naloxone distribution project. Public health and harm reduction partners, known as Tier 1 Distributors, began distributing state-supplied naloxone rescue kits across Maine to clinicians, community partners, and end users. This brief provides information on naloxone distribution and reported overdose reversals by the Tier 1 organizations comprising the MNDI from the initiation of the project through September 2025, with a particular emphasis on the third quarter of 2025. Additionally, subcategories of naloxone distribution from Tier 1 organizations to the Overdose Prevention Through Intensive Outreach Naloxone and Safety (OPTIONS) initiative and syringe services/access programs in 2021 as well as EMS Naloxone Leave Behind Program are provided.

Tier 1 organizations include Bangor Public Health (BPH), Portland Public Health (PPH), MaineGeneral Health (MG), and Maine Access Points (MAP). BPH serves the Aroostook, Downeast, and Penquis public health districts, PPH serves Cumberland and York, and MG serves Central, Midcoast, and Western. MAP distributes naloxone statewide with a particular focus on rural regions. Data from the Office of the Attorney General's (OAG) law enforcement administered naloxone program have also been included to provide an overview of the combined public health, harm reduction, and public safety efforts in Maine.

Currently, it is hard to measure the effectiveness of naloxone distribution because the total number of overdose reversals relies on voluntary reporting. The distribution and reported reversal data tables and figure in this report offer conservative estimates of the lives saved through public health, harm reduction, and safety efforts, which prevented the number of drug deaths from potentially being much higher.

Monthly proportions of 2025 fatalities from January to September averaged 4.9%, moderately lower than the 5.7% in 2024 and the 6.1% in 2023. Monthly proportions in 2025 ranged from a high of 6.1% in February to a low of 4.1% in May.¹

¹ (Sorg et al. 2025). Additional resources, data, and visualizations are available at the Maine Drug Data Hub: <https://mainedrugdata.org/>.




Figure 1: County-level naloxone distribution levels per 100 residents (with point of initial township distribution indicated by star) by the Maine Naloxone Distribution Initiative from July through September 2025.

Note: BPH naloxone purchase and distribution has been delayed Jul–Sep 2025 due to pending contracting delays, which has decreased naloxone distribution for the northern sector of the state.

Public Health—Tier 1 Distributors

During the third quarter of 2025 (July–September):

28,420 doses of naloxone have been distributed
264 overdose reversals have been voluntarily reported.

From July 2019 through September 2025 (MNDI project-to-date totals):

738,008 doses of naloxone have been distributed
9,984 overdose reversals have been voluntarily reported.

Public Safety—Law Enforcement Agencies

During the third quarter of 2025 (July–September):

404 doses of naloxone have been distributed
16 overdose reversals have been voluntarily reported.

From July 2019 through September 2025:

23,012 doses of naloxone have been distributed
1,892 overdose reversals have been voluntarily reported.

Table 1 Doses of naloxone distributed by Tier 1 distributors and OAG

	2019–2023	2024	Jan–Mar 2025	Apr–Jun 2025	Jul 2025	Aug 2025	Sep 2025	Total
BPH (IN)	96692	43628	3612	31332	8	84	38	175394
BPH (RI)	0	4416	48	4104	0	0	0	8568
BPH (IM)	0	0	0	13300	0	0	0	13300
PPH (IN)	83639	36706	6260	9266	2078	3238	2656	143843
PPH (IM)	1714	1934	500	844	214	50	150	5406
PPH (RI)	0	0	0	0	0	4	0	4
MG	76354	34888	8206	16450	1954	4014	4512	146378
MAP (IM)	146481	16654	5440	3424	1180	1862	1978	177019
MAP (IN)	35738	14698	1450	318	0	0	0	52204
MAP (RI)	0	2454	4858	4180	1086	2012	1302	15892
OAG	18324	3180	420	684	192	64	148	23012
Total	458942	158558	30794	83902	6712	11328	10784	761020

Notes: (1) Unit is doses for all values. (2) IM = intramuscular; IN = intranasal; RI = RiVive®. All values are IN unless otherwise indicated. (3) MAP distribution initially included state-supplied and nonstate-supplied naloxone. (4) 2019 data is for July through December only. (5) A revision has been made to BPH January and July, 2020 and March 2021 and PPH April 2021, Jan 2022 and MG March 2020, October, November, December 2021 and March, April 2022. OBG 2019, 2020, 2021 and 2022. (5) Table 1 includes corrections for MAP reporting that include a decrease in IN doses and an increase in IM doses. 1957 doses of IN naloxone were removed from distribution data from 07/2019 to 07/2023 and 13926 doses of IM naloxone were added to distribution data from 07/2019 to 07/2023. (6) Beginning June of 2024, the MNDI will be purchasing and distributing lower dose (3mg) naloxone (RiVive®). (7) BPH naloxone purchase and distribution has been delayed Jul–Sep 2025 due to pending contracting delays.

Table 1.1 Doses of naloxone distributed by Tier 1 distributors to OPTIONS liaisons (subcategory of total distribution)

	2021– 2023	2024	Jan– Mar 2025	Apr– Jun 2025	Jul 2025	Aug 2025	Sep 2025	Total
BPH	7012	5326	768	6376	0	0	0	19482
PPH	4150	2548	728	816	0	792	744	9778
MG	9292	4720	1416	1128	192	552	264	17564
Total	20454	12594	2912	8320	192	1344	1008	46824

Notes: (1) Unit is doses for all values.

Table 1.2 Doses of naloxone distributed by Tier 1 distributors through syringe services/ access programs (subcategory of total distribution)

	2021– 2023	2024	Jan– Mar 2025	Apr– Jun 2025	Jul 2025	Aug 2025	Sep 2025	Total
BPH	20034	9764	456	22364	0	0	0	52618
PPH	25511	9536	2486	3798	718	508	792	43349
MG	8120	2836	344	438	216	92	166	12212
MAP	97894	32596	11476	7986	2096	3120	2956	158124
Total	151559	54732	14762	34586	3030	3720	3914	266303

Notes: (1) Unit is doses for all values. (2) A revision has been made to BPH March, June, September of 2021 January, April and May of 2022 as well as PPH April 2021 and February of 2023. (3) Missing data for January 2021 for PPH.

Table 1.3 Doses of naloxone distributed by Tier 1 distributors to EMS Naloxone Leave Behind Program (subcategory of total distribution)

	2022– 2023	2024	Jan– Mar 2025	Apr– Jun 2025	Jul 2025	Aug 2025	Sep 2025	Total
BPH	1628	884	142	274	8	84	38	3058
PPH	1228	510	70	250	32	40	76	2206
MG	2022	1308	210	246	174	312	266	4538
Total	4878	2702	422	770	214	436	380	9802

Notes: (1) Unit is doses for all values. (2) The EMS Leave Behind Program was launched in January of 2022. TIs are to provide EMS agencies across the state with kits of naloxone to provide to anyone who has refused EMS transport.

Table 2 Number of overdose reversals voluntarily reported to Tier 1 distributors (by individuals or Tier 2 distributors) and overdose reversals reported by OAG law enforcement agencies through the reporting tool called ODMAP

	2019–2023	2024	Jan–Mar 2025	Apr–Jun 2025	Jul 2025	Aug 2025	Sep 2025	Total
BPH	2382	551	68	153	34	40	26	3254
PPH	1344	402	51	52	10	16	17	1892
MG	836	216	32	26	7	6	3	1126
MAP	3063	362	47	43	18	14	68	3615
OAG	1703	130	15	28	3	8	5	1892
OD-ME app	77	14	1	0	1	0	4	97
Total	9405	1675	214	302	73	84	123	11876

Notes: (1) Reversal totals are conservative estimates as not all reversals are reported. (2) OD-ME app is a mobile phone app developed in 2020 to support naloxone administration. (3) Overdose reversal figures may increase as backdated Tier 2 distributor and OAG incident reports are received. (4) 2019 data is July through December only. (5) Law enforcement agencies that receive naloxone from the OAG and report reversals through ODMAP are now being included. ODMAP reversal data has been added from July 2019 to present. (6) A revision has been made to MAP 2022 and PPH February 2023 reversal reports as well as OAG Q1 2023